Glucagon is a 29-amino acid peptide hormone that plays a critical counter-regulatory role to insulin in glucose homeostasis. It was discovered in 1923 as a hyperglycemic factor in pancreatic extracts by Kimball and Murlin, who named it for its ability to increase blood glucose. The peptide is derived from the proglucagon precursor protein, which undergoes tissue-specific post-translational processing to yield glucagon in pancreatic alpha cells and other peptides like GLP-1 and GLP-2 in intestinal L-cells. Its primary physiological significance lies in its role as the body’s principal hormone for raising blood glucose levels during fasting, exercise, and stress, making it essential for preventing hypoglycemia. Glucagon’s actions extend beyond glucose metabolism to include effects on lipid metabolism, energy expenditure, and cardiovascular function, establishing it as a key regulator of metabolic fuel mobilization.
Quick Facts
| Also Known As | GCG, GRPP, GLP-1, GLP-2, Oxyntomodulin, Glicentin-related polypeptide |
|---|---|
| Sequence | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT |
| Molecular Formula | C153H225N43O49S |
| Molecular Weight | 3482.7 Da |
| PubChem CID | 16132283 |
Research Parameters
| Half-Life | ~3-6 minutes (plasma half-life) |
|---|---|
| Stability | Lyophilized powder is stable for 24 months when stored at -20°C, protected from light and moisture. Reconstituted in sterile water or buffer, it is stable for up to 24 hours at 2-8°C. For long-term storage of reconstituted peptide, aliquoting and storage at -20°C or -80°C is recommended to minimize degradation from repeated freeze-thaw cycles. |
| Solubility | Reconstitute in sterile water, bacteriostatic water (with 0.9% benzyl alcohol), or appropriate acidic buffer (e.g., 0.1% acetic acid) to prevent aggregation. Soluble in aqueous solutions at acidic pH. |
| Vial Size | 1 mg |
| Storage (Lyophilized) | -20°C, protect from light and moisture. For long-term storage, -80°C is recommended. |
| Storage (Reconstituted) | 2-8°C for short-term use (up to 24 hours). For longer storage, aliquot and freeze at -20°C or -80°C. Avoid repeated freeze-thaw cycles. |
| Typical Research Dose | Research diagnostic doses: 500-1000 mcg as a single bolus. Metabolic study infusions: 1-3 ng/kg/min. |
| Cycle Parameters | Not applicable for typical research use. Glucagon is primarily used in acute studies, single diagnostic procedures, or emergency protocols, not in cyclical administration protocols. |
| Amino Acid Count | 29 |
Mechanism of Action
Glucagon exerts its effects primarily by binding to and activating the glucagon receptor (GCGR), a class B G-protein-coupled receptor (GPCR) expressed mainly in the liver, but also in adipose tissue, heart, kidney, and pancreas. Receptor activation triggers intracellular signaling cascades that lead to increased hepatic glucose production and glycogenolysis.
cAMP/PKA Pathway: Glucagon binding activates the stimulatory G protein (Gs), which activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP). cAMP activates protein kinase A (PKA), which phosphorylates key metabolic enzymes. In the liver, PKA phosphorylates and activates phosphorylase kinase, which in turn activates glycogen phosphorylase, leading to glycogen breakdown (glycogenolysis). PKA also phosphorylates and inactivates glycogen synthase, halting glycogen synthesis.
Gluconeogenesis Activation: PKA phosphorylates and regulates transcription factors like CREB (cAMP response element-binding protein), which increases the expression of gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. Concurrently, PKA inhibits glycolysis by phosphorylating and inhibiting pyruvate kinase.
Lipolysis and Ketogenesis: In adipose tissue, glucagon receptor activation stimulates hormone-sensitive lipase via PKA, promoting triglyceride breakdown into free fatty acids and glycerol. The fatty acids are delivered to the liver, where they can be oxidized for energy or converted into ketone bodies (ketogenesis), providing an alternative fuel source during prolonged fasting.
Calcium Signaling: In some cell types, glucagon receptor coupling to Gq proteins can activate phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium stores, which can modulate enzyme activity and secretion processes.
Research Applications
Metabolic Research: Glucagon is a cornerstone model for studying hepatic glucose production, glycogen metabolism, and counter-regulatory hormone responses. Research investigates its role in type 1 and type 2 diabetes, where dysregulated glucagon secretion contributes to hyperglycemia. Studies explore glucagon receptor antagonists for diabetes treatment and dual agonists (e.g., glucagon/GLP-1) for obesity and metabolic syndrome.
Cardiovascular Research: Glucagon has positive inotropic and chronotropic effects on the heart, increasing cardiac output and heart rate. Research examines its potential therapeutic role in acute heart failure, beta-blocker overdose, and as a diagnostic agent in cardiac stress testing. Its effects on vascular tone and blood flow are also areas of investigation.
Gastrointestinal Research: Glucagon inhibits gastric acid secretion and gastrointestinal motility. It is used as a research tool and diagnostic agent to induce temporary relaxation of the smooth muscle in the gastrointestinal tract during endoscopic procedures like endoscopic retrograde cholangiopancreatography (ERCP).
Endocrine and Obesity Research: The interplay between glucagon, insulin, and other gut hormones like GLP-1 is a major focus for understanding appetite regulation and energy balance. Research on glucagon's role in promoting satiety and increasing energy expenditure informs the development of new anti-obesity pharmacotherapies.
Safety & Side Effects
From clinical and animal studies, common side effects are related to its pharmacological actions and include nausea, vomiting, and transient hyperglycemia. Vasodilation and a decrease in blood pressure can occur. Tachycardia and palpitations are reported due to its positive chronotropic effects. Hypokalemia is a potential risk due to intracellular shift of potassium. Allergic reactions, including anaphylaxis, are rare but possible, particularly with formulations containing preservatives or derived from animal sources. Theoretical concerns include the risk of promoting glycogen depletion with repeated high dosing and potential stimulation of insulinoma growth. Anecdotally, in research contexts using higher or repeated doses, reports of headache and dizziness are noted.
Dosage Information
This information is derived from published research and clinical protocols for diagnostic or emergency use. It is presented for research understanding only and does not constitute dosing recommendations.
Typical research and diagnostic doses range from 0.25 to 1 mg (250-1000 mcg) administered as a single bolus. For continuous metabolic studies, doses of 1-3 ng/kg/min via intravenous infusion are used to achieve physiological elevations. The primary route of administration is subcutaneous, intramuscular, or intravenous injection. In emergency settings for severe hypoglycemia, 1 mg is standard. For diagnostic purposes (e.g., cardiac or GI imaging), doses are weight-based, typically 0.5-1 mg IV. Frequency is almost always as a single administration or a short-term infusion. Duration of action from a single bolus is approximately 60-90 minutes.
References
Unger, R.H. & Cherrington, A.D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. Journal of Clinical Investigation, 122(1), 4-12, 2012.
Jiang, G. & Zhang, B.B. Glucagon and regulation of glucose metabolism. American Journal of Physiology-Endocrinology and Metabolism, 284(4), E671-8, 2003.
Müller, T.D., et al. The new biology and pharmacology of glucagon. Physiological Reviews, 97(2), 721-766, 2017.
Dunning, B.E. & Gerich, J.E. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocrine Reviews, 28(3), 253-283, 2007.
Galsgaard, K.D., et al. Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis. American Journal of Physiology-Endocrinology and Metabolism, 314(1), E93-E103, 2018.
Capozzi, M.E., et al. Glucagon lowers glycemia when β-cells are active. JCI Insight, 5(16), e129954, 2019.